GI Dynamics (ASX:GID) has a new global commercial head in Mark Twyman, who was appointed this week alongside Robert Solomon, who will be VP of finance.
Twyman will oversee international expansion of sales and marketing efforts for the Lexington, Mass.-based obesity and Type II diabetes treatment company’s flagship EndoBarrier device.
He has more than two decades’ experience in commercializing health care products, most recently as senior VP and general manager at Genzyme Biosurgery, according to a press release. Much of Twyman’s tenure in health care was spent at Merck, where he spanned a number of sales, marketing and operations roles over a period of 18 years.
"GI Dynamics is at the forefront of a major change that is occurring in diabetes care and weight management, and I am delighted to be leading the commercialization of the EndoBarrier, an innovative therapy for treating Type II diabetes and obesity," Twyman said in prepared remarks. "The treatment of these diseases represents two of the largest health care markets in the world."
The EndoBarrier is a plastic sleeve inserted endoscopically into the small intestine, where it slows the uptake of nutrients from food to induce weight loss and help control the symptoms of diabetes.
It’s been approved for 12 months of treatment in the European Union and is also on the market in Chile, Germany, the United Kingdom and the Netherlands. The company has also received an investigational device exemption approval to commence a pilot trial of the EndoBarrier in the U.S.
GI Dynamics also announced that Solomon will take over accounting and financial reporting activities to support the requirements of commercialization. He also comes from the health arena with recent roles at Ironwood Pharmaceuticals and Targanta Therapeutics.
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
- Dehaier makes changes to the board
Dehaier Medical Systems (NSDQ:DHRM) appointed Weibing Yang and Genhui Chen to its board of directors, taking over for Zheng Liu and Bin Qiu, respectively.
- CorMedix adds pharma vet to board
- CardioMEMS’ Bauer wins Delaney Consulting award
CardioMEMS Inc. CFO Dan Bauer won the Delaney Consulting 2011 Excellence in Finance & Accounting award.
- Ascendx Spine appoints new European sales & marketing manager
Ascendx Spine appointed Maria Pilar Debelius-Kensey as sales & marketing manager of the company’s European market, effective immediately.
- Essilor appoints Sagnières to corner office
European optical device maker Essilor International appointed Huvert Sagnières as chairman & CEO. Current CEO Xavier Fontanet will remain on the board of directors.
- Yadav founder named Spirit of Endeavor finalist
Jay Yadav, CardioMEMS founder & CEO named as Spirit of Endeavor award finalist by TechAmerica and the Technology Assn. of Georgia.
- MedQuist Holdings adds O’Brien to board
Franklin, Tenn.-based electronic health records company MedQuist Holdings Inc. appointed Colin O’Brien to board of directors.
- Elsevier/MEDai put Zajac in charge
Predictive clinical analysis company Elsevier/MEDai put Thoman Zajac in the corner office.
- Medicalis shuffles the deck
San Francisco, Calif.-based Medicalis appointed Jim Boyle as chief operating officer and Guy Anthony as chief financial officer.
Bridgewater, N.J.-based therapeutic product maker adds pharmaceutical vet Matt Duffy to its board of advisors.